CrushSCI.com
42.4平均天数
41中位天数
12最短天数
99最长天数
3,4682025发文量

Paper Review Records

全部论文审稿周期

15 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接

44 天

In Search of Long-Term Disease Control: CAR T-Cell Therapy With Axicabtagene Ciloleucel or Allogeneic Hematopoietic Cell Transplantation Against Relapsed/Refractory Large B-Cell Lymphoma

作者
Markus Maulhardt; Lina J. Kolloch; Gina Westhofen; Enver Aydilek; Margarete E. Laage; Christian Plate; Judith Büntzel; Alexander C. Angleitner; Kristian Thomson; Wolfram Jung; Justin Hasenkamp; Evgenii Shumilov; Gerald G. Wulf展开收起
作者单位
Department of Hematology and Medical Oncology, University Medical Center Goettingen, Goettingen, Germany; Department of Hematology and Oncology, University Hospital Muenster, Muenster, Germany; Evangelisches Klinikum Bethel, University Hospital Bielefeld, Bielefeld, Germany; Department of Hematology, Oncology and Palliative Care, Klinikum Magdeburg, Magdeburg, Germany展开收起
PDF源文件 DOI 网页
31 天

Real-World Delivery, Dose Adaptation, and Molecular Monitoring of Gilteritinib, Venetoclax, and Azacitidine in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

作者
Meiling Chen; Yuanzhong Chen; Shaoyuan Wang; Feng’e Yang; Jing Zheng; Danhui Fu; Jia Lin; Xiaofan Li; Nainong Li展开收起
作者单位
Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China; Translational Medicine Center on Hematology, Fujian Medical University, Fuzhou, Fujian, China; Hematopoietic Stem Cell Transplantation Center, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Department of Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China展开收起
PDF源文件 DOI 网页
41 天

Sequential TKI Treatment in Patients With Chronic Phase Chronic Myeloid Leukemia Resistant to Frontline Nilotinib or Dasatinib Therapy. A Real-Life Survey From the Italian Campus CML Network

作者
Gabriele Gugliotta; Mario Annunziata; Isabella Capodanno; Davide Rapezzi; Immacolata Attolico; Marianna Caramella; Iolanda D. Vincelli; Antonella R. Rossi; Mario Tiribelli; Alessandra Malato; Michele Cimminiello; Vincenzo Accurso; Massimiliano Bonifacio; Sara Galimberti; Giuseppina Loglisci; Elisabetta Abruzzese; Monica Bocchia; Antonella Gozzini; Micaela Bergamaschi; Maria C. Miggiano; Agostino Tafuri; Grazia Sanpaolo; Anna R. Scortechini; Monica Crugnola; Debora Luzi; Luigiana Luciano; Gianni Binotto; Roberto Latagliata; Fausto Castagnetti; Alessandro Allegra; Giorgina Specchia; Uros Markovic; Gianantonio Rosti; Robin Foà; Giuseppe Saglio; Massimo Breccia; Fabio Stagno展开收起
作者单位
Institute of Hematology “Seràgnoli”, IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy; Hematology Unit, Cardarelli Hospital, Naples, Italy; Hematology Unit, Azienda Unità Sanitaria Locale - IRCCS, Reggio Emilia, Italy; S.C. Ematologia, Cuneo, Italy; Hematology and Stem cell Transplantation Unit, Bari, Italy; SC Hematology, Niguarda “Ca Granda” Hospital, Milan, Italy; Dipartimento Emato-Oncologia A.O.“Bianchi-Melacrino-Morelli”, Reggio Calabria, Italy; Division of Hematology and BMT, Department of Medical Area, University of Udine, Udine, Italy; UOC Oncoematologia, Palermo, Italy; Hematology and Bone Marrow Transplantation Unit, San Carlo Hospital, Potenza, Italy; UO di Ematologia, Divisione di Oncologia, AOU Policlinico “Giaccone” Università degli Studi di Palermo, Palermo, Italy; Department of Engineering for Innovation Medicine, Section of Innovation Biomedicine, Hematology Area, University of Verona, Verona, Italy; Department of Clinical and Experimental Medicine, Section of Hematology, University of Pisa, Pisa, Italy; Hematology Unit, “Vito Fazzi” Hospital, Lecce, Italy; Hematology Department, “S. Eugenio” Hospital, Tor Vergata University, Rome, Italy; Hematology Unit, University of Siena, Siena, Italy; Hematology Unit, AOU Careggi, University of Florence, Florence, Italy; IRCCS Ospedale Policlinico S. Martino, Dipartimento di Oncologia ed Ematologia, Dipartimento di Oncologia, S.S.D Malattie del Sangue e Neoplasie Degli Organi Emolinfopoietici, Genova, Italy; Hematology Department, San Bortolo Hospital, Vicenza, Italy; Hematology Unit, University Hospital Sant'Andrea-Sapienza, Rome, Italy; Division of Hematology, Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy; Hematology Unit, Azienda Ospedaliero Universitaria Ospedali Riuniti, Ancona, Italy; Hematology Unit, University Hospital of Parma, Parma, Italy; Onco-Hematology Department, AO Santa Maria, Terni, Italy; Division of Hematology and Bone Marrow Transplantation, University of Naples Federico II, Naples, Italy; Department of Medicine, Hematology and Clinical Immunology, Padua School of Medicine, Padua, Italy; Hematology Unit, Viterbo, Italy; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; Hematology Section, AOU Policlinico “G. Martino”, University of Messina, Messina, Italy; Division of Hematology, A.O.U. “Policlinico-San Marco”, University of Catania, Catania, Italy; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy; Hematology, Department of Translational and Precision medicine, Sapienza University of Rome, Rome, Italy; Divisione Universitaria di Ematologia e Terapie Cellulari, Torino, Italy展开收起
PDF源文件 DOI 网页
84 天

Immunoglobulin D-Associated AL Amyloidosis: Clinical Features and Outcomes

作者
Sarika D. Gurnani; Andrew Staron; Lisa M. Mendelson; Natasha J. Burke; Vaishali Sanchorawala展开收起
作者单位
Amyloidosis Center, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA展开收起
PDF源文件 DOI 网页
71 天

Safe Integration of Radiation Therapy With Bispecific Antibodies in Relapsed/Refractory B-cell Lymphomas

作者
Jonathan A. Baron; Monica Chelius; Gurbani Singh; Michael D. Schad; Melanie Berger; Emeline R. Chong; Colin J. Thomas; Jordan S. Carter; Michael R. Cook; Sunita D. Nasta; Daniel J. Landsburg; Stefan K. Barta; Jakub Svoboda; Stephen J. Schuster; Nikhil Yegya-Raman; Michael J. LaRiviere; John P. Plastaras; Elise A. Chong; Harper Hubbeling展开收起
作者单位
Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA; Division of Hematology and Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA展开收起
PDF源文件 DOI 网页
23 天

Clonal Hematopoiesis in Newly Diagnosed Multiple Myeloma: Associations With Neutropenia, Supportive Care Burden, and Survival

作者
Ahmet Yigitbasi; Fulya Oz Puyan; Hakki Onur Kirkizlar; Tugcan Alp Kirkizlar; Nuray Can; Ebru Tastekin; Seyma Keles Karahan; Elif Gulsum Umit; Ahmet Muzaffer Demir展开收起
作者单位
Department of Hematology, Faculty of Medicine, Trakya University, Edirne, Türkiye; Department of Pathology, Faculty of Medicine, Trakya University, Edirne, Türkiye; Department of Internal Medicine, Faculty of Medicine, Trakya University, Edirne, Türkiye展开收起
PDF源文件 DOI 网页

FAQ

Clinical Lymphoma Myeloma & Leukemia审稿要多久?

截至2026-11-14,CrushSCI 收录了 Clinical Lymphoma Myeloma & Leukemia 的 15 篇完整审稿记录。最快一篇从收稿到录用用了 12 天(Knowledge, Awareness, and Practice Patterns of Nephrologists in the Diagnosis and Management of Multiple Myeloma (MIND-MM Study): A Cross-Sectional, Web-Based, CHERRIES-Compliant Survey with Position Statement from the Indian Myeloma Academic Groupe (IMAGe) and Indian Society of Nephrology (ISN),2026-05-31 收稿,2026-06-12 录用),最慢一篇用了 99 天;平均 42.4 天,中位数 41 天。

Expert Matching · Case Demo

把投稿要求,转成可验证的期刊方案

说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。

我们会在半小时内回复。

CrushSCI 在线

客户询问

我是环境工程专业,需要一篇 SCI,希望 3 个月内见刊。没有基金,也没有大牛挂名,可以投哪些期刊?

CrushSCI回复

可以。先按 90 天时限做可行性筛选,同步查找无基金、无知名作者挂靠的典型论文案例,作为选刊依据。重点核对研究质量与期刊 scope。

拟题建议
《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》

样本口径2026 年最近 5 篇有效论文样本

平均审稿59.6 天

中位数65 天

Contact CrushSCI

联系 CrushSCI

留下手机号或微信号,我们将与你确认学术润色、结构优化或一对一辅导咨询需求。

我们会在半小时内回复。

当前选择:学术咨询服务

预留联系方式

也可以直接发送邮件至 leader@crushsci.com

手机号和微信号至少填写一项,仅用于本次咨询联系,不会公开。